62 DAFTAR PUSTAKA
1. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10. doi:10.1186/1471- 2407-10-337
2. Alam A. Chemotherapy Treatment and Strategy Schemes: A Review. Open Access J Toxicol. 2018;2(5). doi:10.19080/oajt.2018.02.555600
3. hafiz S, Amaar DS, Bastawesy DR, et al. Study the Effect of Chemotherapy on the Cardiac Function. Int J Adv Res. 2017;5(2):2519-2527.
doi:10.21474/ijar01/3435
4. Mele D, Rizzo P, Pollina A V., et al. Cancer therapy-induced cardiotoxicity:
Role of ultrasound deformation imaging as an aid to early diagnosis.
Ultrasound Med Biol. 2015;41(3):627-643.
doi:10.1016/j.ultrasmedbio.2014.11.015
5. Lustberg MB, Zareba KM. Anthracycline cardiotoxicity. Circ Cardiovasc Imaging. 2016;9(8). doi:10.1161/CIRCIMAGING.116.005324
6. Karim S, Bhandari U, Kumar H, et al. Doxorubicin induced cardiotoxicity and its modulation by drugs. Indian J Pharmacol. 2001;33(3):203-207.
7. Santos DS dos, Goldenberg RC dos S. Doxorubicin-Induced Cardiotoxicity:
From Mechanisms to Development of Efficient Therapy. Cardiotoxicity.
Published online 2018:3-24. doi:10.5772/intechopen.79588
8. Puzzovivo A, Fioretti AM, Minoia C, et al. Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkin’s Lymphoma: The Tei Index Evaluation. J Pers Med. 2022;12(2).
doi:10.3390/jpm12020290
9. Shakir D. Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. J Clin Med Res. 2009;1(1):8-12.
doi:10.4021/jocmr2009.02.1225
10. Albakri A. Chemotherapy-induced cardiomyopathy: a review of literature on
63 clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy. Med Clin Arch. 2018;2(4):1-14.
doi:10.15761/mca.1000140
11. Sawicki KT, Sala V, Prever L, et al. Preventing and Treating Anthracycline Cardiotoxicity: New Insights. Annu Rev Pharmacol Toxicol. 2021;61:309- 332. doi:10.1146/annurev-pharmtox-030620-104842
12. Abbas AA, Alazmii AAM. Anthracycline ‑ Induced Cardiac Toxicity : A Clinical Review. Published online 2021. doi:10.4103/ijmpo.ijmpo
13. Mistiaen W. Effect of Doxorubicin on Cardiac Myocytes: Role of Apoptosis, Autophagy and other Proteolytic Pathways. Int J Cardiol Lipidol Res.
2016;3(2):31-43. doi:10.15379/2410-2822.2016.03.02.01
14. Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest.
2014;124(2):617-630. doi:10.1172/JCI72931
15. Timm KN, Tyler DJ. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity. Cardiovasc Drugs Ther.
2020;34(2):255-269. doi:10.1007/s10557-020-06941-x
16. Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: A common factor in the complex milieu of anthracycline cardiotoxicity. Oxid Med Cell Longev. 2017;2017.
doi:10.1155/2017/1521020
17. Mitry MA, Edwards JG. Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC Hear Vasc. 2016;10:17-24.
doi:10.1016/j.ijcha.2015.11.004
18. Rodrigues PG, Miranda-Silva D, Costa SM, et al. Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle. Am J Physiol -
Hear Circ Physiol. 2019;316(3):H459-H475.
doi:10.1152/ajpheart.00401.2018
19. Wenningmann N, Knapp M, Ande A, et al. Insights into doxorubicin- induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol. 2019;96(2):219-232.
64 doi:10.1124/mol.119.115725
20. Kibudde S, Mondo CK, Kibirige D, et al. Anthracycline induced cardiotoxicity in adult cancer patients: A prospective cohort study from a specialized oncology treatment centre in Uganda. Afr Health Sci.
2019;19(1):1647-1656. doi:10.4314/ahs.v19i1.40
21. Nandennavar M, Sekar A, Karpurmath S. Retrospective study of chemotherapy induced cardiotoxicity from a tertiary cancer centre in South India. Int J Res Med Sci. 2016;4(12):5190-5195. doi:10.18203/2320- 6012.ijrms20163990
22. Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol.
2004;2(3):251-256.
23. Shaikh AS, Alam MM, Mohsin SS, et al. Risk Factors Associated with Anthracycline Induced Cardiac Dysfunction in Pediatric Patients. World J Cardiovasc Dis. 2014;04(07):377-383. doi:10.4236/wjcd.2014.47047 24. Ibrahim O. Anthracycline-induced cardiotoxicity. Türk Kardiyol Dern Arş.
2014;42(3):274-276.
25. Alkuraishy HM, Al-Gareeb AI, Al-hussaniy HA. Doxorubicin-Induced Cardiotoxicity: Molecular Mechanism and Protection by Conventional Drugs and Natural Products. Int J Clin Oncol Cancer Res . 2017;2(2):31-44.
doi:10.11648/j.ijcocr.20170202.12
26. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525-533.
doi:10.1136/hrt.2007.136093
27. El-Dakroory S. Doxorubicin Cardiotoxicity in Acute Lymphoblastic Leukemia: Possible Protective Role of Grape Seed Extract Proanthocyanidins. Br J Med Med Res. 2014;4(13):2555-2567.
doi:10.9734/bjmmr/2014/6088
28. van Dalen E. Anthracycline-Induced Cardiotoxicity during and after Treatment for Childhood Cancer. Vol 42.; 2006.
29. Oktem G, Ayla S, Seckin I, et al. Doxorubicin induced nephrotoxicity:
65 Protective effect of nicotinamide. Int J Cell Biol. 2011;2011.
doi:10.1155/2011/390238
30. William. Tinjauan Pustaka Patofisiologi dan Patogenesis Kardiomiopati. FK Ukrida. Published online 2012.
31. Rahmadin B, Okta Safda D, Maysara F, et al. Kardiomiopati. Fak Kedokt Univ Andalas. 2016;(2):1-23.
32. Domercant J, Polin N, Jahangir E. Cardio-oncology: A focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. Ochsner J.
2016;16(3):250-256.
33. National Cancer Institute. Common Terminology Criteria for Adverse
Events. 2017. Available from:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/c tcae_v5_quick_reference_8.5x11.pdf. 2017;(13):1-147.
doi:10.1039/DT9930001947
34. Mizia-Stec K, Gociska A, Mizia M, et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol. 2013;71(7):681-690.
doi:10.5603/KP.2013.0154
35. Ahmed SN, Jhaj R, Sadasivam B, et al. Prediction of left ventricular mass index using electrocardiography in essential hypertension – A multiple linear regression model. Med Devices Evid Res. 2020;13:163-172.
doi:10.2147/MDER.S253792
36. Bahadır A, Kurucu N, Kadıoğlu M, et al. The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study. Turkish J Hematol. 2014;31(1). doi:10.4274/tjh.2013.0013
37. Maifitrianti, Sutandyo N, Andrajati R. Factor That Affect the Decline of Left Ventricular Ejection Fraction in Cancer Patients Treated With Doxorubicin At Dharmais. Media Farm. 2015;12:233-246.
38. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol.
66 2004;22(10):1864-1871. doi:10.1200/JCO.2004.06.033
39. Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non- Hodgkin’s lymphoma. J Clin Oncol. 2008;26(19):3159-3165.
doi:10.1200/JCO.2007.14.1242
40. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
J Clin Oncol. 2007;25(25):3808-3815. doi:10.1200/JCO.2006.10.4976 41. Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for
detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer. 2013;16(2):178-183.
doi:10.4048/jbc.2013.16.2.178
42. Khattry N, Malhotra P, Grover A, et al. Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy. Indian J Med Paediatr Oncol.
2009;30(01):9-13. doi:10.4103/0971-5851.56329
43. Moulin M, Piquereau J, Mateo P, et al. Sexual dimorphism of doxorubicin- mediated cardiotoxicity potential role of energy metabolism remodeling.
Circ Hear Fail. 2015;8(1):98-108.
doi:10.1161/CIRCHEARTFAILURE.114.001180
44. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer.
2003;97(11):2869-2879. doi:10.1002/cncr.11407
45. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation.
2015;131(22):1981-1988. doi:10.1161/CIRCULATIONAHA.114.013777 46. Chen D-S, Yan J, Yang P-Z. Cardiomyocyte Atrophy, an Underestimated
Contributor in Doxorubicin-Induced Cardiotoxicity. Front Cardiovasc Med.
2022;9(February):1-12. doi:10.3389/fcvm.2022.812578
47. Jordan JH, Castellino SM, Meléndez GC, et al. Left ventricular mass change after anthracycline chemotherapy. Circ Hear Fail. 2018;11(7).
doi:10.1161/CIRCHEARTFAILURE.117.004560
67 48. Jeyaprakash P, Sangha S, Ellenberger K, et al. Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: A systematic review and meta-analysis of placebo arms from randomized controlled trials.
J Am Heart Assoc. 2021;10(6). doi:10.1161/JAHA.120.018802
49. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines:
Develop. Circulation. 2009;119(14).
doi:10.1161/CIRCULATIONAHA.109.192065
50. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Br J Cancer. 2002;86(11):1697-1700. doi:10.1038/sj.bjc.6600346
51. Kim DY, Youn JC, Park MS, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: A 10-year multicenter cohort study. J Cardiol. 2019;74(2):175-181.
doi:10.1016/j.jjcc.2019.02.001
52. Shyama VN. Early Cardiac Changes Due to Doxorubicin Based Chemotherapy and Radiotherapy in Early and Locally Advanced Carcinoma Breast Patients: An Observational Study. J Nucl Med Radiat Ther. 2015;s7.
doi:10.4172/2155-9619.s7-004
53. Mobaraki M, Faraji A, Zare M, et al. Molecular mechanisms of cardiotoxicity: A review on the major side-effects of doxorubicin. Indian J Pharm Sci. 2017;79(3):335-344. doi:10.4172/pharmaceutical- sciences.1000235
